logo
Plus   Neg
Share
Email

JD Sports Says Not Appropriate To Provide FY Outlook Amid COVID-19

JD Sports Fashion Plc. (JD.L) on Tuesday said that all of its stores are closed in UK, United States and Europe due to COVID-19. The company said its Board does not believe it appropriate to provide financial guidance for the current financial year ending January 30, 2021.

In its update on the impact of coronavirus or COVID-19 on its business, the company said its trading websites continue to accept and fulfil orders. But, it has seen a resilient performance to date in most territories.

The company is pursuing a number of measures to preserve capital across all aspects of business and thereby limit the level of cash burn.

The Board also notes the request from the Financial Conduct Authority over the weekend for all listed companies to observe a moratorium on the publication of results for at least two weeks.

The company would announce a revised date for the publication of the results in due course, which is likely to be in the second half of May.

Peter Cowgill said, "... the Group is experiencing major disruption to our business operations as we seek to protect our colleagues and customers from the effects of COVID-19. .. JD continues to offer a market leading, multichannel proposition in Sports Fashion Retail and we are confident that we will emerge from the current challenges in a strong position to resume our previous positive momentum."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
Follow RTT